opioid use disorder
Pain · 2019–2021
3decisions
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| buprenorphine Maintenance and initiation treatment of opioid use disorder/dependence, with or without prior stabilisation on sublingual buprenorphine or… | Nov 2021 | Recommended with restriction | 1 individuals Better Access Australia |
| buprenorphine Treatment of opioid use disorder (opioid dependence) within a framework of medical, social and psychological treatment. | Mar 2019 | Deferred | none received |
| buprenorphine Treatment of opioid use disorder (opioid dependence) within a framework of medical, social and psychological treatment, in patients stabilised on sublingual… | Nov 2019 | Recommended | no section in document |
Who spoke
Better Access Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.